Prior to joining Eris, Ranganathan was Commercial Director, Women's Health, Metabolics, and International Business at Abbott India Limited
EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin
Both organisations enter into a long- term collaboration to expand patient access in India
Eris Lifesciences enters into term loan agreement with Citi Bank
Eris Lifesciences has reported total income of Rs. 403.80 crores during the period ended March 31, 2023
Eris Lifesciences will be assigned the trademark of these brands by Dr. Reddy's for a consideration of Rs. 275 crore
_256_384.jpg)
The deal will be financed by Rs 300 crore of internal accruals and Rs 350 crore of borrowings
The new greenfield manufacturing facility will be operated alongside the Guwahati facility as a parallel unit thereby helping mitigate the risks of a single-location operation
Eris Lifesciences has reported total income of Rs.1220.57 crores during the 12 months period ended March 31, 2021
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
Subscribe To Our Newsletter & Stay Updated
